Universal Navigation

Join or Renew Your Membership Join Now

S38 - Headache: Clinical Trials II

Event Time:	Wednesday May 8, 2019 1:00 pm to 3:00 pm
Topic(s):	Headache
Director(s):
Description:
Completion Message:
CME Credits:	2
Core Competencies:

Program Speakers - Tentative
Start/End Time	Title	Faculty
2:40 PM - 3:00 PM	Q&A Panel with Authors	Faculty

Disclosures
Speaker	Disclosure

Abstract Presenters
Start Time	Pub.	Title	Presenter
1:00 PM	001	Long-Term Impact of Fremanezumab on Response Rates: Results of a 1-Year Study	Disclosure: Dr. Newman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Alder, Amgen, Biohaven,Novartis, Teva, Supernus and Theranica. Dr. Newman has received personal compensation in an editorial capacity for Springer Scientific.
1:00 PM	002	Efficacy of Erenumab in Chronic Migraine Patients with Medication Overuse and Prior Preventive Treatment Failure	Disclosure: Dr. Dodick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with David W. Dodick reports the following conflicts: Personal fees: Amgen, Association of Translational Medicine, University Health Network, Daniel Edelman Inc., Autonomic technologies, Axsome, Aural Analytics, Allergan, Alder, Biohaven, Charleston Laboratories, Dr Reddy's Laboratories/Promius, Electrocore LLC, Eli Lilly, eNeura, Neurolief, Novartis, Ipsen, Impel, Satsuma, Supernus, Sun Pharma (India), Theranica, Teva, Vedanta, WL Gore, Nocira, PSL Group Services, University of British Columbia, , XoC, Zosano, ZP Opco, Foresite Capital, Oppenheimer. CME fees or Royalty payments Healthlogix, Medicom Worldwide, Medlogix Communications, Mednet, Miller Medical, PeerView, WebMD Health/Medscape, Chameleon, Academy for Continued Healthcare Learning, Universal meeting management, Haymarket , Global Scientific Communications, Global Life Sciences, Global Access Meetings, UpToDate (Elsevier), Oxford University Press, Cambridge University Press, Wolters Kluwer Health; Stock options: Aural analytics, Healint, Theranica, Second Opinon/Mobile Health, Epien, GBS/Nocira, Matterhorn/Ontologics, King-Devick Technologies. Consulting without fee: Aural Analytics, Healint, Second Opinion/Mobile Health, Epien; Board of Directors: Epien, Matterhorn/Ontologics, King-Devick Technologies. Patent :17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis without fee. Professional society fees or reimbursement for travel: American Academy of Neurology, American Brain Foundation, American Headache Society, American Migraine Foundation, International Headache Society, Canadian Headache Society. Other: Use agreement through employer: Myndshft. Dr. Dodick has received compensation for serving on the Board of Directors of Stock options: Aural analytics, Healint, Theranica, Second Opinon/Mobile Health, Epien, GBS/Nocira, Matterhorn/Ontologics, King-Devick Technologies. Consulting without fee: Aural Analytics, Healint, Second Opinion/Mobile Health, Epien; Board of Directors: Epien, Matterhorn/Ontologics, King-Devick Technologies. Dr. Dodick holds stock and/or stock options in Stock options: Aural analytics, Healint, Theranica, Second Opinon/Mobile Health, Epien, GBS/Nocira, Matterhorn/Ontologics, King-Devick Technologies. Consulting without fee: Aural Analytics, Healint, Second Opinion/Mobile Health, Epien; Board of Directors: Epien, Matterhorn/Ontologics, King-Devick Technologies.
1:00 PM	003	Eptinezumab for the Prevention of Episodic Migraine Through 1 Year: Results from the Phase 3 PROMISE-1 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy?1) Trial	Disclosure: Dr. Saper has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder Biopharmaceuticals, Autonomic Technologies, Biohaven Pharmaceuticals, Eli Lilly, and Teva. Dr. Saper has received research support from Alder Biopharmaceuticals, Allergan, Amgen, Inc., Avanir Pharmaceuticals, Autonomic Technologies, Inc., Biohaven Pharmaceuticals, Colucid Pharm., Dr. Reddy's Laboratories, Eli Lilly, lmpax Pharmaceuticals, Scion Neuro Stim LLC, Teva, and Zosano Pharma..
1:00 PM	004	Long-Term Efficacy and Safety of Fremanezumab in Migraine: Results of a 1-Year Study	Disclosure: Dr. Goadsby has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Reports grants and personal fees from Amgen and Eli Lilly and Company, and personal fees from Alder Biopharmaceuticals, Allergan, Autonomic Technologies Inc., Biohaven Pharmaceuticals Inc., Dr Reddy's Laboratories, Electrocore LLC, eNeura, Impel NeuroPharma, MundiPharma, Novartis, Teva Pharmaceuticals, Trigemina Inc., medicolegal expert advice, Massachusetts Medical Society, UpToDate, Oxford University Press, and Wolters Kluwer; he holds a patent for magnetic stimulation for headache assigned to eNeura without fee.. Dr. Goadsby has received personal compensation in an editorial capacity for Journal Watch- Massachusetts Medical Society. Dr. Goadsby has received research support from Amgen and Eli-Lilly and Company.
1:00 PM	005	Sustained Efficacy Over 1 Year of Treatment With Erenumab: Results From the Extension Phase of the STRIVE Study in Episodic Migraine	Disclosure: Dr. Chou has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Amgen Inc.. Dr. Chou holds stock and/or stock options in Amgen Inc..
1:00 PM	006	Real-world Use of Non-invasive Vagus Nerve Stimulation for Acute Treatment of Pain in Episodic Cluster Headache Attacks: Results From a Patient Registry	Disclosure: Dr. Nagy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen; Eli Lilly and Company; Pernix; Supernus; Xenon; Zosano; electroCore, Inc.; Teva Pharmaceuticals. Dr. Nagy has received research support from Alder BioPharmaceuticals; ATI; Eli Lilly and Company; Teva Pharmaceuticals; Xenon, Biohaven; Allergan.
1:00 PM	007	Reduction in Healthcare Resource Utilization in Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the REPOSE Study	Disclosure: Dr. Kollewe has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc, Ipsen Biopharmaceuticals, Merz Neurosciences, and Biogen.
1:00 PM	008	Efficacy, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine: Results From a Single-Attack Phase 3 Study, ACHIEVE II	Disclosure: Dr. Trugman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc. Dr. Trugman holds stock and/or stock options in Allergan plc. which sponsored research in which Dr. Trugman was involved as an investigator. Dr. Trugman holds stock and/or stock options in Allergan plc.
1:00 PM	009	Patient Global Impression of Change Related to Improvement in Most Bothersome Symptom Following Treatment With Eptinezumab	Disclosure: Dr. Cady has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Full time employee at Alder BioPharmaceuticals, Inc..

Ready to register for the 2019 AAN Annual Meeting?

Related Courses

Saturday, May 4, 2019
9:30 AM-11:30 AM
C14 - Child Neurology: Headache Amy Gelfand MD

Sunday, May 5, 2019
7:00 AM-9:00 AM
C46 - Actualización en dolor de cabeza y trastornos neuromusculares (Update: Headache and Neuromuscular Disorder) Jose Merino MD, MPhil, FAAN, Dario Beltran MD, FAAN
11:30 AM-6:30 PM
P1 - Poster Session 1
1:00 PM-3:00 PM
C53 - Introduction to Primary Headache Disorders: Migraine and Other Primary Headaches Including Tension-Type, Hypnic, Primary Stabbing and Nummular Headache Syndromes, Epicrania Fugax and Retinal Migraine Deborah Friedman MD, MPH, FAAN
3:30 PM-5:30 PM
C70 - Introduction to Primary Headache Disorders: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches Christopher Boes MD, FAAN

Monday, May 6, 2019
9:15 AM-12:00 PM
Contemporary Clinical Issues Plenary Session Randolph Marshall MD, FAAN
11:30 AM-6:30 PM
P2 - Poster Session 2
1:00 PM-3:00 PM
C91 - Neurology Update III: Headache, Neuro-otology, and Epilepsy Ralph Jozefowicz MD, FAAN, Adam Quick MD
S17 - Headache: Clinical Trials I
3:30 PM-5:30 PM
S19 - Child Neurology: Updates in Autism, Migraine, MS, and Stroke
S20 - Headache Imaging and Physiology and Episodic Syndromes Associated with Migraine

Tuesday, May 7, 2019
9:15 AM-11:30 AM
Clinical Trials Plenary Session Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN
11:30 AM-6:30 PM
P3 - Poster Session 3
1:00 PM-3:00 PM
C138 - Hot Topics in Headaches and Related Disorders I: Unusual Headaches, Childhood Headaches, and Concussion Management Amy Gelfand MD
3:30 PM-5:30 PM
C156 - Hot Topics in Headaches and Related Disorders II: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances Andrew Charles MD

Wednesday, May 8, 2019
7:00 AM-9:00 AM
C173 - Skills Workshop: Practical Training in Injection Techniques in the Treatment of Headache Disorders (Registration Required) Amaal Starling MD, Rashmi Halker Singh MD, FAAN
11:30 AM-6:30 PM
P4 - Poster Session 4
11:45 AM-12:30 PM
Eating Your Way to Fewer Migraines Belinda Savage-Edwards MD, FAAN, Chef Tess Connor
1:00 PM-1:45 PM
Headache Neuromodulation Therapy Heidi Schwarz MD, FAAN
1:00 PM-3:00 PM
C187 - Comprehensive Migraine Update I: Migraine Diagnosis, Pathophysiology, and Comorbidities Gretchen Tietjen MD
3:30 PM-5:30 PM
C203 - Comprehensive Migraine Update II: Pharmacologic and Non-Pharmacologic Therapies Gretchen Tietjen MD

Thursday, May 9, 2019
7:00 AM-9:00 AM
C210 - Low and High Pressure Headache: Clinical Presentation and Approach to Evaluation and Management Kathleen Digre MD, FAAN
11:30 AM-6:30 PM
P5 - Poster Session 5
1:00 PM-3:00 PM
C219 - Therapy in Neurology III: Epilepsy and Headache David Dodick MD, FAAN
7:00 PM-10:00 PM
C241 - Case Studies: Challenging Headache Cases Kathleen Digre MD, FAAN

Friday, May 10, 2019
7:00 AM-9:00 AM
C247 - What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders Stephanie Nahas MD, FAAN
11:45 AM-12:45 PM
Friday Grand Finale: Neuroimaging
1:00 PM-3:00 PM
S59 - Migraine: Impact, Treatment Patterns and Resource Utilization

Footer